SCHEMBL3967744

SCHEMBL3967744

Cc1cc(Cn2ccc3cc(C=O)ccc32)c2ccccc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.44
HSP90AA1 P07900 1/20 0.44
CYP2A6 P11509 1/20 0.44
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
APP P05067 3/20 0.41
CYP1A2 P05177 1/20 0.41
ERBB2 P04626 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5405524 0.82 CYP1A2 (0.46) CYP1A2KMT2ANCF1
SCHEMBL3967741 0.81 ERBB2 (0.40) CYP1A2ERBB2SMN1; SMN2MEN1KMT2A
SCHEMBL4048580 0.77 CYP1A2 (0.41) CYP1A2ERBB2SMN1; SMN2MEN1KMT2A
SCHEMBL14207388 0.77 NPC1 (0.67) NPC1HSP90AA1CYP2A6HDAC3HDAC4
SCHEMBL3964970 0.73 CYP1A2 (0.51) CYP1A2SMN1; SMN2KDM4EALDH1A1NCF1
SCHEMBL3969618 0.72 NCF1 (0.49) NPC1CYP1A2SMN1; SMN2MEN1KMT2A
SCHEMBL3969617 0.72 CYP1A2 (0.41) CYP1A2SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL6598929 0.72 PPARG (0.49) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL9287208 0.71 CYP2A6 (0.62) NPC1HSP90AA1CYP2A6HDAC3HDAC4
SCHEMBL29957308 0.71 CYP2A6 (0.62) NPC1HSP90AA1CYP2A6HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 US disclosed
CN-1481377-A Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteinases and TNF-alpha ����˹�ж�-����˹˹����ҩƷ��˾ 2004-03-10 CN disclosed
CN-1420881-A Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha BRISTOL MYERS SQUIBB PHARMACEU (US) 2003-05-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 NPC1 2541/4885HSP90AA1 2427/4885CYP2A6 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.